• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Covidien closes $300 million Oridion deal

Covidien closes $300 million Oridion deal

June 26, 2012 By MassDevice staff

Covidien logo
Oridion Systems logo

As expected, Covidien (NYSE:COV) closed its $300 million merger of Oridion Systems, an Israeli maker of pulse oximetry products.

In the deal, first announced in April, Covidien agreed to pay $23 per share for Oridion. Officials at the Mansfield, Mass.-based company said it plans to roll the company into its respiratory & monitoring solutions division, 1 of 5 operating units in the company’s medical device segment, which brought in over $2 billion in sales during the 3 months ended March 30.

Sign up to get our free newsletters delivered straight to your inbox

 

“The acquisition of Oridion will expand our portfolio with a key monitoring technology,” respiratory and monitoring president Robert White said in a prepared release. “Oridion’s products and technology will complement the company’s pulse oximeter and monitoring product lines, enabling us to offer a complete portfolio of solutions to monitor respiratory function for our customers.”

The deal completes quite a comeback for Oridion, which in January overcame some manufacturing hurdles that saw its entire product line blocked in the U.S.

The FDA banned Oridion from importing any devices into the U.S. after the med-tech maker failed to fix violations at a Jerusalem plant. Shares fell 39% on news of the ban, from $11.00 to $6.65 at market opening Dec. 27.

The federal watchdog agency lifted most of the ban earlier this year, narrowing the prohibition to just 2 Oridion products, specifically the infant/neonatal FilterLine H Set and infant/neonatal VitaLineTM H Set line.

The FDA action came after nearly 6 months of warnings from the agency. Oridion stepped into the FDA’s spotlight in June when an investigation was launched after Philips (NYSE:PHG) recalled 8 lots of infant and neonatal carbon dioxide sampling lines manufactured by Oridion on concerns that they may contain hair-like plastic strands that infants could inhale.

Oridion also markets the Microstream capnography monitors and modules and the etCO2 breathing sampling lines that monitor ventilation.

Filed Under: Mergers & Acquisitions, News Well Tagged With: Covidien, Oridion Systems Ltd.

More recent news

  • Penumbra completes enrollment in pulmonary embolism trial
  • Zoll opens new facility in Rhode Island
  • FDA expands clearance for Inquis Medical’s Aventus thrombectomy system
  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy